The grant provides non-dilutive capital and independent validation, but the company remains pre-revenue with no approved products. Monitor for Phase 1 initiation in Q1 2027 and any interim data readouts from the APOLLO lymphoma trial.
Price Chart
Executive Summary
Marker Therapeutics received a $2.6 million FDA Orphan Products Clinical Trials grant to support a Phase 1 study of its lead MAR-T cell therapy, MT-601, in pancreatic cancer. The non-dilutive funding provides external validation and extends cash runway for a clinical-stage company with no approved products.
Key Financial Metrics
Key Facts
- Awarded $2.6 million from FDA Orphan Products Clinical Trials grants program
- Funding supports Phase 1 study of MT-601 in locally advanced unresectable pancreatic cancer
- FDA received 66 applications and selected 6 projects for funding in FY2026
- Clinical initiation anticipated in Q1 2027
- Prior Baylor Phase 1/2 study showed 84.6% disease control rate and median OS of 14.1 months in pancreatic cancer
- Non-dilutive funding adds to existing NIH SBIR and CPRIT grants for the same program
Financial Impact
$2.6 million non-dilutive grant; extends cash runway for a clinical-stage company with no approved products
Risk Factors
- Clinical-stage company with no approved products or revenue
- Phase 1 pancreatic cancer study has not yet initiated; clinical data may not replicate prior Baylor results
- Small grant ($2.6M) relative to typical clinical trial costs; additional financing likely needed
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3383260 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $1.20 $1.16 | ▼ −3.33% | ▼ −3.67% | $0.9399 (−21.68%) |
Oct 19, 2026 7d ago | Press Release | $1.20 $1.16 | ▼ −3.33% | ▼ −3.67% | $0.9399 (−21.68%) |
Mar 20, 2026 31w ago | DEFA14A | $1.31 $1.26 | ▼ −3.82% | ▼ −3.46% | $0.9399 (−28.25%) |
Mar 19, 2026 31w ago | 8-K | $1.32 $1.34 | ▲ +1.52% | ▲ +3.26% | $0.9399 (−28.80%) |
Mar 18, 2026 31w ago | Press Release | $1.32 $1.34 | ▲ +1.52% | ▲ +3.26% | $0.9399 (−28.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers